Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I intratumoral MIRX002 in recurrent cervical lymph node lesions of head and neck cancer
jRCT2031240644Phase 1Recruiting
- Sponsor
- PURMX Therapeutics
- Start
- Feb 2025
- Modality
- miRNA Mimics → MicroRNA (miRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, miRNA Inhibitors → MicroRNA (miRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of MIRX002 in head and neck squamous cell carcinoma (HNSCC) and cervical lymph node metastasis (CLNM), sponsored by PURMX Therapeutics. Primary endpoints: Dose-limiting toxicity incidence, Adverse events (CTCAE v5.0) and 2 more. Started Feb 2025; status: recruiting.
02
Drugs
MIRX002
03
Conditions
head and neck squamous cell carcinoma (HNSCC)cervical lymph node metastasis (CLNM)
Beyond the preview
Go deeper on jRCT2031240644.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031240644.